Targeted sequencing reveals the relationship between mutations and patients’ clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma

References

• Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the Global Cancer Statistics 2020. Chin Med J. 2021;134(7):783–791. [PMID: 33734139]
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947. [PMID: 12075054]
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–2323. [PMID: 19038878]
   PubMed Web of Science ®Google Scholar
• Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848–2856. [PMID: 26240231]
   PubMed Web of Science ®Google Scholar
• Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–858. [PMID: 33657296]
   PubMed Web of Science ®Google Scholar
• Ondrisova L, Mraz M. Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies. Front Oncol. 2020;10:591577. [PMID: 33154951]
   PubMed Web of Science ®Google Scholar
• Ganapathi KA, Brown LE, Prakash S, et al. New developments in non-Hodgkin lymphoid malignancies. Pathology. 2021;53(3):349–366. [PMID: 33685720]
   PubMed Web of Science ®Google Scholar
• de Miranda NF, Georgiou K, Chen L, et al. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood. 2014;124(16):2544–2553. [PMID: 25171927]
   PubMed Web of Science ®Google Scholar
• Rosenquist R, Bea S, Du MQ, et al. Genetic landscape and deregulated pathways in B-cell lymphoid malignancies. J Intern Med. 2017;282(5):371–394. [PMID: 28631441]
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407. [PMID: 29641966]
   PubMed Web of Science ®Google Scholar
• Fan Z, Pei R, Sha K, et al. Comprehensive characterization of driver genes in diffuse large B cell lymphoma. Oncol Lett. 2020;20(1):382–390. [PMID: 32565964]
   PubMed Web of Science ®Google Scholar
• Li Z, Yu F, Ye W, et al. Clinical features and prognostic significance of NOTCH1 mutations in diffuse large B-cell lymphoma. Front Oncol. 2021;11:746577. [PMID: 34956871]
   PubMedGoogle Scholar
• Shen R, Xu PP, Wang N, et al. Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. Clin Transl Med. 2020;10(7):e221. [PMID: 33252851]
   PubMed Web of Science ®Google Scholar
• Ma J, Yan Z, Zhang J, et al. A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression. Biomark Res. 2020;8:33.
   PubMed Web of Science ®Google Scholar
• Moore MM, Chua W, Charles KA, et al. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87(4):504–508. [PMID: 20147899]
   PubMed Web of Science ®Google Scholar
• Cox MC, Nofroni I, Ruco L, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008;49(9):1745–1751. [PMID: 18798109]
   PubMed Web of Science ®Google Scholar
• Oki Y, Yamamoto K, Kato H, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol. 2008;81(6):448–453. [PMID: 18691256]
   PubMed Web of Science ®Google Scholar
• Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–568.e514. [PMID: 32289277]
   PubMed Web of Science ®Google Scholar
• Guo B, Huang Y, Duan Y, et al. SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups. Cancer Med. 2022;11(5):1281–1291. [PMID: 35106936]
   PubMed Web of Science ®Google Scholar
• Nagarajan P, Onami TM, Rajagopalan S, et al. Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene. 2009;28(8):1053–1062. [PMID: 19137022]
   PubMed Web of Science ®Google Scholar
• Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604–616. [PMID: 30859597]
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011;25(9):1502–1509. [PMID: 21606957]
   PubMed Web of Science ®Google Scholar
• Watanabe R, Tomita N, Itabashi M, et al. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol. 2014;92(3):204–210. [PMID: 24283206]
   PubMed Web of Science ®Google Scholar
• Montalban C, Abraira V, Arcaini L, et al. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol. 2012;159(2):164–171. [PMID: 22924582]
   PubMed Web of Science ®Google Scholar
• Donadieu J, Auclerc MF, Baruchel A, et al. Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables. Fralle Group. French Acute Lymphoblastic Leukaemia Study Group. Br J Haematol. 1998;102(3):729–739. [PMID: 9722300]
   PubMed Web of Science ®Google Scholar
• Chen H, Qin Y, Yang J, et al. The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: an analysis of 1007 patients in the rituximab era. Leuk Res. 2021;110:106715. [PMID34598076.
   PubMed Web of Science ®Google Scholar
• Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020;135(20):1759–1771. [PMID: 32187361]
   PubMed Web of Science ®Google Scholar
• Stefancikova L, Moulis M, Fabian P, et al. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Int J Oncol. 2011;39(6):1413–1420. [PMID: 21874232]
   PubMed Web of Science ®Google Scholar
• Qin W, Fu D, Shi Q, et al. Molecular heterogeneity in localized diffuse large B-cell lymphoma. Front Oncol. 2021;11:638757. [PMID: 34557402]
   PubMed Web of Science ®Google Scholar
• Juskevicius D, Jucker D, Klingbiel D, et al. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort. J Hematol Oncol. 2017;10(1):70.
   PubMedGoogle Scholar
• Young KH, Leroy K, Moller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an International Collaborative Study. Blood. 2008;112(8):3088–3098. [PMID: 18559976]
   PubMed Web of Science ®Google Scholar
• Young KH, Weisenburger DD, Dave BJ, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood. 2007;110(13):4396–4405. [PMID: 17881637]
   PubMed Web of Science ®Google Scholar
• Guo D, Hong L, Ji H, et al. The mutation of BTG2 gene predicts a poor outcome in primary testicular diffuse large B-cell lymphoma. J Inflamm Res. 2022;15:1757–1769. [PMID: 35300216]
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang J. T-cell receptors provide potential prognostic signatures for breast cancer. Cell Biol Int. 2021;45(6):1220–1230. [PMID: 33527533]
   PubMed Web of Science ®Google Scholar
• Mansouri L, Noerenberg D, Young E, et al. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood. 2016;128(23):2666–2670. [PMID: 27670424]
   PubMed Web of Science ®Google Scholar
• Mansouri L, Sutton LA, Ljungstrom V, et al. Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med. 2015;212(6):833–843. [PMID: 25987724]
   PubMed Web of Science ®Google Scholar
• Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886–1918. [PMID: 22408430]
   PubMed Web of Science ®Google Scholar
• Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(4):1398–1403. [PMID: 23292937]
   PubMed Web of Science ®Google Scholar
• Xu H, Duan N, Wang Y, et al. The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma. Pathology. 2020;52(2):206–212. [PMID: 31883669]
   PubMed Web of Science ®Google Scholar